$57.6 Million

G1 Therapeutics

Follow-on Offering

Lead Left Bookrunner, November 2022

G1 Therapeutics, Inc. (“G1” or the “Company”) (GTHX) is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the company’s first commercial product, COSELA (trilaciclib). G1 has a deep clinical pipeline and is executing a tumor-agnostic development plan evaluating trilaciclib in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers.